Halozyme Therapeutics Inc HALO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HALO is a good fit for your portfolio.
News
-
Mahesh Krishnan Elected to Halozyme's Board of Directors
-
Halozyme to Report First Quarter 2024 Financial and Operating Results
-
Halozyme to Participate in Upcoming Investor Conferences
-
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
-
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Trading Information
- Previous Close Price
- $39.12
- Day Range
- $38.23–38.75
- 52-Week Range
- $29.85–45.00
- Bid/Ask
- $37.13 / $52.47
- Market Cap
- $4.89 Bil
- Volume/Avg
- 693,350 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 15.76
- Price/Sales
- 6.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 8.23%
Company Profile
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 373
- Website
- https://www.halozyme.com
Comparables
Valuation
|
Metric
|
HALO
|
SGEN
|
MRNA
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.76 | — | 39.52 |
Price/Book Value | 58.18 | 16.92 | 2.93 |
Price/Sales | 6.22 | 18.61 | 6.01 |
Price/Cash Flow | 12.08 | — | — |
Price/Earnings
HALO
SGEN
MRNA
Financial Strength
|
Metric
|
HALO
|
SGEN
|
MRNA
|
|---|---|---|---|
Quick Ratio | 5.07 | 1.96 | 3.21 |
Current Ratio | 6.64 | 2.67 | 3.42 |
Interest Coverage | 19.57 | — | −113.82 |
Quick Ratio
HALO
SGEN
MRNA
Profitability
|
Metric
|
HALO
|
SGEN
|
MRNA
|
|---|---|---|---|
Return on Assets (Normalized) | 16.03% | −13.05% | −20.12% |
Return on Equity (Normalized) | 199.98% | −17.35% | −26.85% |
Return on Invested Capital (Normalized) | 18.45% | −16.86% | −26.68% |
Return on Assets
HALO
SGEN
MRNA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ktcbnvnsv | Vqx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kkltdxj | Zgtvx | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Myfbnhpgj | Zdfkc | $97.8 Bil | |
MRNA
| Moderna Inc | Qxwjzlfhv | Pfpm | $38.8 Bil | |
ARGX
| argenx SE ADR | Ppffksm | Chrn | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Cszwczxm | Tdmjf | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lsxbxjvb | Jglqwlp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Flvbbwbgf | Bvlkqpn | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wyctsppgxd | Gmkmjx | $12.5 Bil | |
INCY
| Incyte Corp | Gjnzydtg | Jzfnwz | $11.5 Bil |